AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01010178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macrolid, Theophylline, Inhaler Corticosteroids
Description: we have no permission to include them in detail because of privacy policy of mentioned journal for publication
Study NCT01683526 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Study NCT01683526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Video laryngoscopy (Glidescope)
Study NCT05324696 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: autoinflation device
Description: The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
Study NCT05324696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: autoinflation device
Description: The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
Study NCT05324696 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: autoinflation device
Description: The authors developed a new standardized, inexpensive and simple device, based on Moniri. The Device is formed by a T tube with a unidirectional valve. A mask with the capacity of covering the child's mouth and nose, providing hermetic seal, and a balloon are connected to 2 ends of the T tube. Blowing the balloon trough the mask, with different types of maneuvers, will force the opening of the Eustachian tube and subsequent reabsorption of the middle ear effusion.
Study NCT02198352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS - in single rising doses
Study NCT02198352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05286346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil 245mg
Description: 1 tablet q.d. for 48 weeks
Study NCT05286346 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300mg
Description: 1 tablet q.d. for 48 weeks
Study NCT02179619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermalax(Deep)
Description: Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
Study NCT02179619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermalax(Deep)
Description: Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
Study NCT02179619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
Study NCT02179619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
Study NCT01499589 — intervention group
Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: regional anesthesia procedure
Study NCT02979327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adderall capsule
Description: 25 mg orally one time
Study NCT02979327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Looks exactly like the study drug, but it contains no active ingredient. Taken one time.
Study NCT00622895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI
Study NCT00622895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow transplantation
Description: Undergo transplantation
Study NCT00622895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reduced intensity allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation
Study NCT02527577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: injection Hour (H) 0, H12 ; H24, H36 ; H48
Study NCT03276455 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous CD34+ cells genetically modified
Description: Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10\^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10\^6/Kg and a maximum dose of 20 x 10\^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
Study NCT03089385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertension tool
Description: An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
Study NCT04339244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RALRP under lower mean BP
Description: RALRP under regulation of lower mean BP
Study NCT04339244 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RALRP under lower mean BP
Description: RALRP under regulation of highly normal mean BP
Study NCT00827138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCC-2036
Description: 150 mg BID tablets, continuous dosing of 28 day cycles
Study NCT03800940 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulography and trans-drain occlusion
Description: 1. Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.~2. Trans-drain occlusion: a 0.035-inch guidewire is inserted via the puncture needle. The drain tube is removed, cut at 4 cm proximal to the skin fixation site, and preserved for reinsertion. After inserting a 40cm 5Fr KMP catheter over the guidewire, the guidewire is removed. Afte rinsing the KMP catheter with 3ml 5% glucose water, withdraw the catheter and simultaneously inject glue (33%, 1:2, 0.5ml of NBCA + 1ml Lipiodol) into the catheter until the proximal 5cm of the catheter remains inside the tract. The guidewire is re-inserted through the catheter, and then the original drain tube is re-inserted over the guidewire. The guidewire is removed and the drain is fixed.
Study NCT03800940 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Fistulography
Description: Fistulography: an 18G needle is inserted into the tube and diluted contrast medium is slowly injected into the tube.
Study NCT01037192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vancomycin
Description: vancomycin 30 mg/kg intravenous administered once daily
Study NCT01037192 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
Study NCT03338413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Management Training
Description: 9 GMT modules will be administered in 9X2 hour sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving.
Study NCT03338413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: 9 modules will be administered in 9x1 hour session (ten groups). Computerized Cognitive Training using commercially available web-based platforms based on neuroplasticity, developed to target skills such as attention, memory, speed of processing and executive functioning. Homework assignment between sessions.
Study NCT00622895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00622895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00622895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study NCT00622895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Punch biopsy of skin involved with scleroderma
Study NCT01745809 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Description: Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
Study NCT02058901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Study NCT04500704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Almonertinib
Description: Almonertinib 110mg PO once daily. A cycle of treatment is defined as 21 days of once daily treatment. Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study NCT04500704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib plus carboplatin and pemetrexed
Description: Almonertinib 110mg PO once daily in combination with pemetrexed (500 mg/m2) plus carboplatin (AUC=5) on Day 1 of 21day cycles (every 3 weeks) for 4-6 cycles, followed by Almonertinib daily with pemetrexed maintenance (500 mg/m2) every 3 weeks.
Study NCT00093613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO
Study NCT00093613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02481635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT02481635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Study NCT02481635 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Study NCT02481635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Study NCT00650858 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Description: 0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
Study NCT00650858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Description: 0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
Study NCT02630953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Original Tailored Intervention
Description: The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
Study NCT02630953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Tailored Intervention
Description: Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
Study NCT01154647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: citalopram
Description: intravenous
Study NCT01154647 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 ml 0.9 % NaCl
Description: intravenous
Study NCT02385279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiStent
Description: Percutaneous Coronary Intervention
Study NCT02385279 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE EES
Description: Percutaneous Coronary Intervention
Study NCT01961115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO
Study NCT01961115 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELITAC 12.1 Peptide Vaccine
Description: Given ID/SC
Study NCT01021189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
Study NCT01021189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution Dose single and followed by 7-day multiple dosing.
Study NCT00559078 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Hour-long, qualitative, phone interview
Study NCT02111044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: octreotide 100 mcg sc t.i.d. for 4 weeks
Study NCT02111044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 500 mcg
Description: ITF2984 500 mcg sc b.i.d for 4 weeks
Study NCT02111044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 1000 mcg
Description: ITF2984 1000 mcg sc b.i.d for 4 weeks
Study NCT02111044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2984 2000 mcg
Description: ITF2984 2000 mcg sc b.i.d for 4 weeks
Study NCT04415398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated flying Drone carrying an Automated external defibrillator (AED)
Description: Totally n=3 drones are equipped with automated external defibrillators (AEDs). These drones are deployed by the dispatch centre to cases of suspected out-of-hospital cardiac (OHCA) as a complement to standard care (ambulance/EMS) over 4 months during daytime Monday to Sunday 08:00-22:00. The bystander onsite receives instructions from the dispatcher to retrieve the AED outside the house when it has been delivered by the drone. The bystander attaches the AED to the patients chest to facilitate early defibrillation.
Study NCT02926703 — intervention group
Intervention type: OTHER
Intervention: Serum lactate and CK concentrations in blood samples
Description: Serum lactate and CK concentrations in blood samples were measured routinely at admission
Study NCT02670603 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EVONAIL® solution
Study NCT02670603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVONAIL® solution
Study NCT03529409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Khanya
Description: This treatment involves integrating a behavioral intervention for substance use with a behavioral intervention for adherence.
Study NCT00933036 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosstrees Pod system for PVA
Description: Minimally invasive spine surgery
Study NCT01011348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 100mg/day for three months
Study NCT00867880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIb
Description: 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
Study NCT00867880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIb
Description: 800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
Study NCT04243668 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTI REFLUX MUCOSAL ABLATION THERAPHY (ARMA)
Description: In patients fulfilling inclusion criteria and willing for ARMA, the procedure involves ablation of the mucosa of the EGJ using TT knife (ARMA). Subsequently, saline solution mixed with indigo-carmine is injected at the submucosa level to raise a submucosal bleb, followed by ablation of the mucosa along the lesser curvature using TT knife.The approximate duration of the procedure is 40min.~Follow up will include objective evaluation of reflux disease with: upper endoscopy, esophageal manometry, pHmetry,reflux questionnaire.
Study NCT00404313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
Study NCT01011348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Coenzyme Q10
Description: 300mg/day for three months
Study NCT01011348 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: Three month period
Study NCT01291602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NXL104
Description: IV Solution
Study NCT01291602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ104
Description: IV Solution
Study NCT01291602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV saline
Study NCT00404313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
Study NCT04002986 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: A blood draw or saliva kit will be provided to collect subject cells
Study NCT00931424 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: valve reconstruction
Description: reconstruct valve at the same time of superficial vein surgery
Study NCT01453231 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thighplasty
Description: Plastic surgery of thigh
Study NCT01651780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
Study NCT01651780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: Unfractionated heparin is an anticoagulant.
Study NCT01755663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine and Metoprolol
Study NCT01755663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine and Metoprolol
Study NCT01207830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo Bypass System
Description: Subject is implanted with the device for up to 3 years.
Study NCT01422993 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 Week Exercise Program
Description: Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
Study NCT02347904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 and Oxaliplatin
Description: Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
Study NCT03725553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intramyometrial Vasopressin
Description: a bolus injection of vasopressin (4 IU) diluted to 2 mL with saline into the myometrium of the placental bed during slow (30-seconds) immediately after delivery, as soon as the umbilical cord was clamped.
Study NCT03725553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: the group received a 10-mL bolus injection of saline into the myometrium during slow (30-seconds)as soon as the umbilical cord was clamped.
Study NCT01017250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery (SRS)
Description: Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
Study NCT01017250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
Study NCT03894345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: Competitive alpha-1 adrenergic receptor blocker which has been used to treat PTSD and Benign Prostatic Hypertrophy